X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs PANACEA BIOTECH - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD PANACEA BIOTECH BIOCON LTD/
PANACEA BIOTECH
 
P/E (TTM) x 82.9 171.2 48.4% View Chart
P/BV x 7.8 3.8 205.1% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 BIOCON LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
PANACEA BIOTECH
Mar-14
BIOCON LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,162149 781.4%   
Low Rs48382 586.3%   
Sales per share (Unadj.) Rs194.684.1 231.2%  
Earnings per share (Unadj.) Rs34.4-18.3 -187.9%  
Cash flow per share (Unadj.) Rs48.3-6.7 -720.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs241.983.7 289.0%  
Shares outstanding (eoy) m200.0061.25 326.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.21.4 307.9%   
Avg P/E ratio x23.9-6.3 -378.8%  
P/CF ratio (eoy) x17.0-17.2 -98.8%  
Price / Book Value ratio x3.41.4 246.4%  
Dividend payout %2.90-   
Avg Mkt Cap Rs m164,4407,074 2,324.4%   
No. of employees `0009.22.8 335.8%   
Total wages/salary Rs m7,4701,449 515.5%   
Avg. sales/employee Rs Th4,213.91,874.1 224.9%   
Avg. wages/employee Rs Th809.0527.0 153.5%   
Avg. net profit/employee Rs Th745.2-407.7 -182.8%   
INCOME DATA
Net Sales Rs m38,9115,154 755.0%  
Other income Rs m1,571100 1,574.1%   
Total revenues Rs m40,4825,254 770.6%   
Gross profit Rs m9,795-766 -1,278.2%  
Depreciation Rs m2,772711 389.9%   
Interest Rs m2601,503 17.3%   
Profit before tax Rs m8,334-2,881 -289.3%   
Minority Interest Rs m16311 1,509.3%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1,61617 9,619.0%   
Profit after tax Rs m6,881-1,121 -613.7%  
Gross profit margin %25.2-14.9 -169.3%  
Effective tax rate %19.4-0.6 -3,324.7%   
Net profit margin %17.7-21.8 -81.3%  
BALANCE SHEET DATA
Current assets Rs m40,4773,810 1,062.3%   
Current liabilities Rs m16,7838,365 200.6%   
Net working cap to sales %60.9-88.4 -68.9%  
Current ratio x2.40.5 529.5%  
Inventory Days Days60156 38.3%  
Debtors Days Days8367 123.2%  
Net fixed assets Rs m45,07314,480 311.3%   
Share capital Rs m1,00061 1,631.3%   
"Free" reserves Rs m47,377903 5,246.0%   
Net worth Rs m48,3775,127 943.5%   
Long term debt Rs m21,0825,832 361.5%   
Total assets Rs m93,94219,433 483.4%  
Interest coverage x33.1-0.9 -3,606.5%   
Debt to equity ratio x0.41.1 38.3%  
Sales to assets ratio x0.40.3 156.2%   
Return on assets %7.62.0 387.0%  
Return on equity %14.2-21.9 -65.0%  
Return on capital %12.63.6 346.7%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m12,9881,539 843.8%   
Fx outflow Rs m7,899942 838.5%   
Net fx Rs m5,089597 852.1%   
CASH FLOW
From Operations Rs m6,400599 1,068.1%  
From Investments Rs m-4,985-438 1,138.4%  
From Financial Activity Rs m-1,775-303 586.6%  
Net Cashflow Rs m-473-141 334.7%  

Share Holding

Indian Promoters % 40.4 74.5 54.2%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.6 1,400.0%  
FIIs % 10.7 1.3 823.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 23.6 84.3%  
Shareholders   109,995 10,259 1,072.2%  
Pledged promoter(s) holding % 0.0 35.1 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  MERCK LTD  NOVARTIS  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS